Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Leridistim

Drug Profile

Leridistim

Alternative Names: Myelopoietin; SC 68420; Stem cell factor - Pharmacia

Latest Information Update: 31 Jul 2000

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmacia Corporation
  • Class Antineoplastics; Colony-stimulating factors; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Granulocyte colony stimulating factor stimulants; Interleukin 3 stimulants; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Stem cell mobilisation

Most Recent Events

  • 31 Jul 2000 Discontinued-III for Stem cell mobilisation in USA (SC)
  • 05 Apr 2000 Monsanto has merged with Pharmacia & Upjohn to form Pharmacia Corporation
  • 20 Jan 2000 Yamanouchi has exercised its option to develop and market leridistim in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top